File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Retrospective review on the use of topical cyclosporin a 0.05% for paediatric allergic conjunctivitis in Hong Kong Chinese

TitleRetrospective review on the use of topical cyclosporin a 0.05% for paediatric allergic conjunctivitis in Hong Kong Chinese
Authors
Issue Date2014
Citation
Scientific World Journal, 2014, v. 2014, p. 396987-396987 How to Cite?
AbstractPURPOSE: To evaluate the efficacy of using topical cyclosporin A 0.05% (Restasis) for the treatment of paediatric allergic conjunctivitis. METHODS: This retrospective study included consecutive cases of paediatric allergic conjunctivitis treated with Restasis between 2010 and 2013. Subjects with follow-up time less than 3 months after using Restasis were excluded. Itch severity score, symptom score, and sign score were compared before (baseline) and 3 months after using Restasis. RESULTS: In 27 eyes of 14 patients (mean age 10.8 +/- 3.2 years), 44.4% had allergic conjunctivitis, 33.3% had vernal keratoconjunctivitis, and 22.2% had atopic keratoconjunctivitis. The mean duration of ocular symptoms was 20.4 +/- 13.2 months. 92.6% of subjects were using steroid eye drop before Restasis. After 3 months of topical Restasis, there were statistically significant reductions in the symptom, sign, and itch severity scores compared with baseline (all P
Persistent Identifierhttp://hdl.handle.net/10722/208476
ISSN
2013 Impact Factor: 1.219
2015 SCImago Journal Rankings: 0.315
PubMed Central ID

 

DC FieldValueLanguage
dc.contributor.authorWu, MMen_US
dc.contributor.authorYau, GSen_US
dc.contributor.authorLee, WYJen_US
dc.contributor.authorWong, ALen_US
dc.contributor.authorTam, VTen_US
dc.contributor.authorYuen, CYen_US
dc.date.accessioned2015-03-11T07:06:16Z-
dc.date.available2015-03-11T07:06:16Z-
dc.date.issued2014en_US
dc.identifier.citationScientific World Journal, 2014, v. 2014, p. 396987-396987en_US
dc.identifier.issn1537-744Xen_US
dc.identifier.urihttp://hdl.handle.net/10722/208476-
dc.description.abstractPURPOSE: To evaluate the efficacy of using topical cyclosporin A 0.05% (Restasis) for the treatment of paediatric allergic conjunctivitis. METHODS: This retrospective study included consecutive cases of paediatric allergic conjunctivitis treated with Restasis between 2010 and 2013. Subjects with follow-up time less than 3 months after using Restasis were excluded. Itch severity score, symptom score, and sign score were compared before (baseline) and 3 months after using Restasis. RESULTS: In 27 eyes of 14 patients (mean age 10.8 +/- 3.2 years), 44.4% had allergic conjunctivitis, 33.3% had vernal keratoconjunctivitis, and 22.2% had atopic keratoconjunctivitis. The mean duration of ocular symptoms was 20.4 +/- 13.2 months. 92.6% of subjects were using steroid eye drop before Restasis. After 3 months of topical Restasis, there were statistically significant reductions in the symptom, sign, and itch severity scores compared with baseline (all P </= 0.001) and 78.6% of subjects were able to be tapered off steroid eye drops. CONCLUSION: Topical Restasis was effective and safe in significantly reducing ocular itchiness, sign, and symptom scores at 3 months after use in paediatric allergic ocular conditions.en_US
dc.languageengen_US
dc.relation.ispartofScientific World Journalen_US
dc.titleRetrospective review on the use of topical cyclosporin a 0.05% for paediatric allergic conjunctivitis in Hong Kong Chineseen_US
dc.typeArticleen_US
dc.identifier.emailLee, WYJ: jackylee@hku.hken_US
dc.identifier.authorityLee, WYJ=rp01498en_US
dc.identifier.doi10.1155/2014/396987en_US
dc.identifier.pmcid4214101-
dc.identifier.scopuseid_2-s2.0-84908328902-
dc.identifier.volume2014en_US
dc.identifier.spage396987en_US
dc.identifier.epage396987en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats